Premium
Serum cytokine measurements and biological therapy of psoriasis – Prospects for personalized treatment?
Author(s) -
Solberg Silje M.,
Sandvik Lene F.,
Eidsheim Marianne,
Jonsson Roland,
Bryceson Yenan T.,
Appel Silke
Publication year - 2018
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/sji.12725
Subject(s) - psoriasis , psoriasis area and severity index , medicine , cytokine , immune system , logistic regression , interleukin 17 , disease , dermatology life quality index , interleukin , tumor necrosis factor alpha , immunology , gastroenterology
Abstract Psoriasis is an immune‐mediated disease where the IL ‐23/Th17 axis as well as TNF comprise main targets of biological therapy. Immune profiling has so far not been embraced as a clinical tool. We aimed to investigate relationships between individual serum cytokine levels in 40 psoriasis patients before and after receiving biological therapy and Psoriasis Area and Severity Index ( PASI ) and Dermatological Life Quality Index ( DLQI ). Serum concentration of 25 cytokines was determined by Luminex technology. Mean PASI and DLQI decreased by 71% and 65%, respectively. Increase of IL ‐2 positively correlated with improvement of PASI and DLQI . Moreover, increase of IL ‐5, IL ‐10, IL ‐12, IL ‐22 and GM ‐ CSF correlated with treatment effect. Notably, logistic regression revealed four times higher risk of having severe psoriasis when IL ‐17A increased by 1 pg/ mL ( OR : 4.06, P < 0.05). Selected serum cytokines might constitute useful biomarkers for monitoring disease activity and optimizing therapeutic strategies in psoriasis patients.